Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Predictors of cancer risk in the long-term solid-organ transplant recipient|
|Citation:||Transplantation, 2014; 97(6):605-611|
|Publisher:||Lippincott Williams and Wilkins|
|Sam N. Sherston, Robert P. Carroll, Paul N. Harden, Kathryn J. Wood|
|Abstract:||Malignancy is increasingly the leading cause of mortality in solid-organ recipients. Cancer incidence among the transplant population is overall threefold to fivefold higher than the general population with poorer outcomes for late-stage disease. Insights into the identification of patients at particular risk of developing a posttransplantation malignancy are imperative to ensure appropriate measures are instigated to reduce associated morbidity and mortality. This review focuses on potential clinical, immunologic, and genetic translational markers aimed at identifying long-term solid-organ transplant patients at high risk of developing cancer.|
|Keywords:||Cancer; Posttransplantation; Markers; Malignancy; Transplantation; Long-term|
|Rights:||© 2013 by Lippincott Williams & Wilkins.|
|Appears in Collections:||Aurora harvest 2|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.